Home > News > EBMT-HARMONY joint session. Inviting bone marrow transplant professionals to become involved.

EBMT-HARMONY joint session. Inviting bone marrow transplant professionals to become involved.

February 22, 2022 16:14 - x 00, 0 - 00:00

#bigdataforbloodcancer, Cancer research

Big Data innovations offer exciting opportunities for bone marrow transplant professionals and hematologists to rapidly select the most promising treatment for their patients. HARMONY invites bone marrow transplant professionals to become involved

Experts of the HARMONY Alliance will be presenting at the 48th EBMT Annual Meeting. This year's meeting of the European Society for Blood and Marrow Transplantation will be organized as a hybrid event. EBMT2022 will take place from 19-23 March 2022. It is possible for a limited amount of attendees to participate in person at the Prague Congress Centre in Prague, Czech Republic. The EBMT is a valued HARMONY and HARMONY PLUS Partner. 


EBMT-HARMONY Joint Session

Learn about Big Data innovations and new ‘tools’ to rapidly select the most promising treatment for blood cancer patients. The EMBT-HARMONY joint session (JS05) is virtual and launched on March 19, at 09:50 at the virtual meeting platform. The EMBT2022 virtual meeting platform will be accessible until end of May 2022.

Connect with us

EBMT has been an official Partner in HARMONY from the very beginning. The main reasons why HARMONY and EBMT foster its collaboration is that the same major aim are shared: to improve the outcomes of patients with Hematologic Malignancies. Data sharing is the key to success. HARMONY and EBMT have a lot to offer each other. HARMONY gladly would like to offer EBMT community members the opportunity to be involved in what might be the largest public-private partnership in hematologic malignancies worldwide. EBMT members can propose research projects that exploit the HARMONY Big Data Platform and use HARMONY’s Big data and Artificial Intelligence tools to establish new patterns of association between data and outcomes.

Big data for blood cancer

The HARMONY Alliance is a public-private partnership of more than 100 European organizations such as hospitals, research institutes, patient organizations, pharmaceutical companies, regulatory agencies, IT companies and medical associations such as EBMT and EHA. The joint mission is to accelerate the development of more effective treatments for patients with Hematologic Malignancies (blood cancers). With a unique Big Data Platform, the HARMONY Alliance is fully equipped to facilitate state-of-the-art research into Hematologic Malignancies. HARMONY would like to inform bone marrow transplant professionals about the opportunities to become involved. 

Big data for big questions

HARMONY’s unique research infrastructure includes a data lake with almost 100,000 patient data sets identified, which has been developed in the past five years. Careful procedures have been installed to ensure the anonymization and quality of the data. In addition, HARMONY data scientists have developed sophisticated methods for data harmonization and analysis. Various Research Project teams are currently using the HARMONY Big Data Platform to answer critical research questions that cannot be addressed with other methods. Among other things, the results may allow physicians to determine the prognosis of patients more precisely and to tailor the treatment choice to the prognosis. HARMONY has already achieved fascinating research results in its mission towards better and faster treatment for patients with Hematologic Malignancies. Overview of 2021 highlights >

#bigdataforbloodcancer: Accelerating Better and Faster Treatment for Patients with Hematologic Malignancies.

The HARMONY Alliance (HARMONY and HARMONY PLUS) is a public-private partnership for Big Data in Hematology. Our mission is to unlock and spread valuable knowledge on hematologic malignancies (blood cancers) among a large number of stakeholders, with the goal to harness and mine Big Data to speed up the development of improved treatments for patients and more effective treatment strategies.


Receive the latest news. Click here to subscribe!